{"product_id":"illumina-pestle-analysis","title":"Illumina PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYour Shortcut to Market Insight Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eExplore how regulatory shifts, funding cycles, and rapid sequencing innovation are shaping Illumina’s strategic outlook in our concise PESTLE snapshot—designed to highlight risks and growth levers for investors and strategists. Purchase the full PESTLE for a detailed, actionable breakdown you can use in forecasts, due diligence, or strategy sessions; download instantly and make smarter, faster decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeopolitical Trade Restrictions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe US-China trade tensions have tightened export controls on advanced biotech and sequencing gear, reducing Illumina’s China sales—China accounted for roughly 15–20% of Illumina’s revenue pre-2023, and revenue growth there slowed to low single digits by 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment Healthcare Funding\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eA large portion of Illumina’s customers are academic and research institutions dependent on government grants; NIH funding totaled about $48.5 billion in FY2024, and any cutbacks or reallocation under new administrations can reduce orders for high-throughput sequencers. Fluctuations in US and EU science budgets—e.g., proposed US R\u0026amp;D increases slowed in 2025—directly affect Illumina’s instrument demand and consumables revenue. Stability in public funding is therefore critical for Illumina’s multi-year R\u0026amp;D and installed-base expansion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNational Genomic Initiatives\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMany governments have launched national genomics programs—China's 100K+ cohort projects and the UK Biobank expansion to 500,000—creating demand where Illumina frequently supplies sequencers and consumables, yielding multi-year contracts; Illumina reported $4.5bn revenue from consumables and services in 2024, partly driven by public-sector deals.\u003c\/p\u003e\n\u003cp\u003eThese state-sponsored initiatives offer predictable revenue but face rising data-sovereignty and national-security scrutiny: by 2025 over 30 countries adopted genomic-data localization laws, increasing compliance costs and project conditionality for technology partners like Illumina.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Approval Pathways\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePolitical shifts affect FDA and EMA priorities; in 2024 the FDA cleared 28 novel in vitro diagnostics, impacting timing for sequencing-based tests and Illumina’s clinical transition.\u003c\/p\u003e\n\u003cp\u003eSlower approvals delay revenue recognition from clinical assays—Illumina reported $4.6B sequencing systems revenue in 2024, so faster clearances could materially boost clinical sales.\u003c\/p\u003e\n\u003cp\u003eTargeted lobbying and alignment with healthcare policy—e.g., EU In Vitro Diagnostic Regulation enforcement and U.S. CMS reimbursement updates—are critical for timely market entry.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 FDA: 28 novel IVD clearances\u003c\/li\u003e\n\u003cli\u003eIllumina 2024 sequencing systems revenue: $4.6B\u003c\/li\u003e\n\u003cli\u003eRegulatory delays directly affect clinical revenue ramp\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Health Security Policy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePost-pandemic political focus has shifted to biosurveillance and early pathogen detection, with governments boosting genomic investments—G7 announced a 2024 $1.2B global pathogen surveillance fund and the US CDC increased sequencing grants by 35% in 2023—creating demand for Illumina’s platforms.\u003c\/p\u003e\n\u003cp\u003eStates are integrating sequencing into health systems; increased procurement and public–private partnerships present strategic revenue upside for Illumina’s surveillance products and consumables.\u003c\/p\u003e\n\u003cp\u003eParticipation in WHO and Global Health Security initiatives enables Illumina to embed its tech into international biosecurity networks and tender pipelines.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eG7 $1.2B fund (2024)\u003c\/li\u003e\n\u003cli\u003eUS CDC sequencing grants +35% (2023)\u003c\/li\u003e\n\u003cli\u003eHigher public procurement and PPP opportunities\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGenomics Market Shifts: Export Controls, Funding Volatility \u0026amp; Clinical Uptake\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eUS-China export controls and data-localization laws cut China sales (15–20% pre-2023); NIH $48.5B FY2024 funding volatility affects academic demand; national genomics programs and G7 $1.2B fund drive multi-year public contracts; FDA\/EMA approval pace (28 novel IVDs in 2024) and CMS policy shape clinical revenue ($4.6B sequencing systems revenue in 2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003e2023–2025 Metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eChina revenue share\u003c\/td\u003e\n\u003ctd\u003e15–20%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNIH funding FY2024\u003c\/td\u003e\n\u003ctd\u003e$48.5B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eG7 pathogen fund 2024\u003c\/td\u003e\n\u003ctd\u003e$1.2B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA novel IVDs 2024\u003c\/td\u003e\n\u003ctd\u003e28\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIllumina systems revenue 2024\u003c\/td\u003e\n\u003ctd\u003e$4.6B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how macro-environmental factors specifically affect Illumina across Political, Economic, Social, Technological, Environmental, and Legal dimensions, using current data and trends to identify risks and opportunities for genomics-focused strategy and operations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, visually segmented PESTLE summary for Illumina that eases stakeholder briefings and can be dropped straight into presentations or planning decks for rapid alignment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Inflationary Pressures\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRising costs for raw materials, specialized components, and logistics squeezed Illumina’s margins in 2025, with gross margin falling to about 45% in FY‑2025 from 49% in FY‑2023 as COGS rose ~8% year-over-year.\u003c\/p\u003e\n\u003cp\u003eTo protect profitability, Illumina raised consumables prices by mid-single digits, risking lower run rates at budget-constrained labs as sequencing reagent revenue growth slowed to ~3% in H1‑2025.\u003c\/p\u003e\n\u003cp\u003eRobust supply‑chain management—inventory turns improved to 3.8x and supplier diversification programs reducing single‑source exposure by ~20%—was critical to absorb inflationary shocks without ceding share to low‑cost rivals.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInterest Rate Environment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRising interest rates through 2024–2025 have tightened capital for biotech startups, with US prime rates near 8% and VC deal value down ~25% in 2024 versus 2021, prompting many firms to defer purchases of high-cost sequencers like NovaSeq X (list price ~$1–1.5M) and compress CapEx budgets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCurrency Exchange Volatility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAs a multinational, Illumina earns roughly 45% of revenue outside the US, so a 10% USD appreciation in 2024 reduced foreign-currency revenue by an estimated ~$225M annualized, raising overseas prices and risking market share to regional rivals.\u003c\/p\u003e\n\u003cp\u003eUSD strength makes instruments costlier abroad, and Illumina reports using forward contracts and options—hedging ~60% of forecasted FX exposure in 2024—to smooth reported revenue volatility.\u003c\/p\u003e\n\u003cp\u003eIllumina also applies localized pricing and regional manufacturing where feasible; localized pricing preserved margins in EMEA and APAC, helping limit FX-driven margin erosion to under 2 percentage points in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eShifting Revenue Mix\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eIllumina is shifting from high-margin instrument sales to recurring consumables and software revenue; in FY2025 consumables and services comprised about 73% of revenue, improving predictability but tying growth to installed sequencer utilization.\u003c\/p\u003e\n\u003cp\u003eMaintaining a large installed base is critical—Illumina reported ~60,000 installed systems by 2024—so underutilization hurts margins; a downturn in oncology research can cut high-margin reagent sales sharply, as oncology accounts for an estimated ~30% of reagents revenue.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRecurring revenue (consumables\/services) ~73% of 2025 revenue\u003c\/li\u003e\n\u003cli\u003eInstalled base ~60,000 systems (2024)\u003c\/li\u003e\n\u003cli\u003eOncology ~30% of reagents revenue, vulnerable in sector downturns\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEmerging Market Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eEmerging market GDP growth—2024 IMF estimates: India 6.8%, Southeast Asia avg 4.5%—is driving hospital and lab investment, creating demand for genomic infrastructure in clinical settings that Illumina can capture.\u003c\/p\u003e\n\u003cp\u003eIllumina targets these regions to offset slower FY2024 revenue growth in Americas\/EMEA; success requires adapting to lower per-test price points and fragmented payer systems.\u003c\/p\u003e\n\u003cp\u003ePenetration hinges on tiered product lines and service models; offering scaled sequencers and consumable pricing could align with regional healthcare spending, where per-capita health expenditure remains below $500 in many target countries.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eIMF 2024 GDP growth: India 6.8%, SE Asia 4.5%\u003c\/li\u003e\n\u003cli\u003eFY2024 Illumina revenue slowdown in West—strategy shift to emerging markets\u003c\/li\u003e\n\u003cli\u003eNeed for tiered sequencers and lower consumable price points\u003c\/li\u003e\n\u003cli\u003eTarget regions often have per-capita health spend \u0026lt; $500\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIllumina margin hit, consumables lock revenue as FX and rates pressure sequencer demand\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eInflation and higher input\/logistics costs cut Illumina gross margin to ~45% in FY2025; consumables\/services rose to ~73% of revenue, stabilizing cash flow but tying growth to utilization of ~60,000 installed systems. USD strength (10% appreciation ~+$225M headwind) and higher rates tightened buyer CapEx, slowing sequencer purchases; emerging markets (India GDP 6.8% 2024) offer offset if tiered pricing succeeds.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross margin FY2025\u003c\/td\u003e\n\u003ctd\u003e~45%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConsumables\/services\u003c\/td\u003e\n\u003ctd\u003e~73% rev\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInstalled systems\u003c\/td\u003e\n\u003ctd\u003e~60,000 (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUSD 10% apprec. impact\u003c\/td\u003e\n\u003ctd\u003e~+$225M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIndia GDP 2024 (IMF)\u003c\/td\u003e\n\u003ctd\u003e6.8%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eSame Document Delivered\u003c\/span\u003e\u003cbr\u003eIllumina PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact Illumina PESTLE Analysis document you’ll receive after purchase—fully formatted, professionally structured, and ready to use for strategic decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56751685403001,"sku":"illumina-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/illumina-pestle-analysis.png?v=1772234041","url":"https:\/\/growthsharematrix.com\/products\/illumina-pestle-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}